IGF system components as prognostic markers in breast cancer

Breast Cancer Research and Treatment

Volumn 47, Issue 3, 1998, Pages 295-302

  Lee, Adrian V ^a   Hilsenbeck, Susan G ^a   Yee, Douglas ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast cancer; IGF; IGFBP; Prognosis; Treatment

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FAMILY; TREATMENT PLANNING;

BREAST NEOPLASMS; HUMANS; PROGNOSIS; SOMATOMEDINS;

EID: 0031964011     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005915420341     Document Type: Article

References (42)

1. Baker J, Liu J-P, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73-82, 1993
2. Liu J-P, Baker J, Perkins AS, Robertson E, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-1) and type 1 IGF receptor (igf1r). Cell 75:59-72, 1993
3. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55:249-252, 1995
4. Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother 49:415-421, 1995
5. Yee D: The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Treat 32: 85-95, 1994
6. Lee AV, Weng C-N, Jackson JG, Yee D: Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152: 39-47, 1997
7. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995
8. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, Korach KS: Peptide growth factors cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estiadiol. Endocrinol 137:1735-1744, 1996
9. Yee D, Paik S, Levovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509-517, 1989
10. Yee D, Cullen K, Paik S, Perdue J, Hampton B, Schwartz A, Lippman M, Rosen N: Insulin-like growth factor Il mRNA expression in human breast cancer. Cancer Res 48:6691-6696, 1988
11. Paik S: Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22:31-38, 1992
12. Giani C, Cullen KJ, Campani D, Rasmussen A: IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat 41:43-50, 1996
13. Cullen K, Yee D, Sly W, Perdue J, Hampton B, Lippman M, Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50:48-53, 1990
14. Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch T, Cullen KJ: Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 55:2448-2454, 1995
15. Osborne CK, Coronado EB, Kitten LJ, Arteaga CR, Fuqua SAW, Ramasharma K, Marshall M, Li CH: Insulin-like growth factor-II (IGF-II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3:1701-1709, 1989
16. Lee AV, Darbre P, King RJB: Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol 99:211-220, 1994
17. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP: Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in human breast cancer. Br J Cancer 74:1242-1247, 1996
18. Toropainen EM, Lipponen PK, Synanen KJ: Expression of insulin-like growth factor II in human breast cancer as related to established prognostic factors and long-term prognosis. Anticancer Res 15:2669-2674, 1995
19. Peyrat JP, Bonneterie J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29:492-497, 1993
20. Pollack MN, Huynh HT, Lefebvre SP: Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22:91-100, 1992
21. Barni S, Lissoni P, Brivio F, Fumugalli, Merlini D, Cataldo M, Rovelli F, Tancini G: Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 80:212-215, 1994
22. Bhatavedar JM, Patel DD, Karelia NH, Vora HH, Ghosh N, Shah NG, Balar DB, Trivedi SN: Tumor markers in patients with advanced breast cancer as prognosticators: A preliminary study. Breast Cancer Res Treat 30:293-297, 1994
23. Peyrat J-P, Bonneterre J, Beuscart R, Djiane J, Demaille A: Insulin-like growth factor I receptors in human breast cancer and their relationship to estradiol and progesterone receptors. Cancer Res 48:6429-6433, 1988
24. Pekonen F, Partanen S, Makinen T, Rutanen EM: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48:1343-1347, 1988
25. Foekens JA, Portengen H, Jansen M, Klun G: Insulin-like growth factor-I receptors and insulin-like growth factor-I-like activity in human primary breast cancer. Cancer 63:2139-2147, 1989
26. Bonneterre J, Peyrat JP, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor I receptors in human breast cancer. Cancer Res 50: 6931-6935, 1990
27. Papa V, Gliozzo B, Clark G, McGuire W, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine I, Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736-3740, 1993
28. Papa V, Hartmann KKP, Rosenthal SM, Maddux BA, Siiteri PK, Goldfine ID: Progestins induce down-regulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: Potential autocrine role of IGF-II. Mol Endocrinol 5:709-717, 1991
29. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1-15, 71-85, 1992
30. Berns EMJJ, Klijn JGM, van Staveren IL, Portengen H, Foekens JA: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036-1039, 1990
31. Nishimito I, Murayama Y, Katada T, Ui M, Ogata E: Possible direct linkage of insulin-like growth factor II receptor with guanine nucleotide-binding proteins. J Biol Chem 264:14029-14038, 1989
32. Karner C, Nurnberg B, Uhde M, Braulke T: Mannose-6-phosphate/insulin-like growth factor II receptor fails to interact with G-proteins. Analysis of mutant cytoplasmic receptor domains. J Biol Chem 270:287-295, 1995
33. McGuire W Jr, Jackson JG, Figueroa JA, Shimasaki SA, Powell DR, Yee D: Regulation of insulin-like growth factor binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84:1336-13411, 1992
34. Yee D, Sharma J, Hilsenbeck SG: Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst 86:1785-1789, 1994
35. Shao Z-M, Sheikh MS, Ordonez JV, Feng P, Kute T, Chen J-C, Aisner S, LeRoith D, Roberts CT, Fontana J: IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma. Cancer Res 52: 5100-5103, 1992
36. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK: Insulin-like growth factor binding protein secretion by breast cancer cell lines: correlation with estrogen receptor status. Endocrinol 127:2679-2686, 1990
37. Yee D, Favoni R, Lippman M, Powell D: Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat 18:3-10, 1991
38. Rocha R, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D: Insulin-like growth factor binding protein-3 (BP3) mRNA and protein expression are correlated in primary breast cancer tissue; higher levels are detected in tumors with poor prognostic features. J Natl Cancer Inst 88:601-606, 1996
39. Rocha RL, Hilsenbeck SG, Jackson JG, Van Den Berg CL, Weng C-N, Lee AV, Yee D: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival. Clinical Cancer Research 3:103-109, 1997
40. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77:229-233, 1993
41. Diamandis EP, Yu H, Sutherland DJA: Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32:301-310, 1994
42. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger B, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649, 1995